Lantern Pharma Completes LP-184 Trial, 63 Patients Show Promising Efficacy
Lantern Pharma announced additional details and clinical insights from its completed Phase 1a dose-escalation study of LP-184 as well as highlights from its recent webinar. The clinical trial demonstrated durable disease control in 63 heavily pre-treated patients with advanced solid tumors, many of which had DNA damage repair pathway deficiencies. The clinical trial met all primary endpoints for safety, tolerability, and established a clear recommended phase 2 dose. Building on these Phase 1a results, Lantern is advancing an ambitious precision oncology development strategy featuring multiple biomarker-guided Phase 1b/2 clinical trials in triple-negative breast cancer, glioblastoma multiforme, non-small cell lung cancer and advanced urothelial carcinoma. Overall, 63 heavily pre-treated patients with advanced solid tumors enrolled; trial achieved 54% disease control rate in patients at or above therapeutic dose levels, demonstrating promising activity in DNA damage repair-deficient cancers. Patients with stage 4 squamous lung cancer, thymic carcinoma, and gastrointestinal stromal tumor remain on treatment with 12+ to 23+ months of ongoing clinical benefit and meaningful tumor reductions after failing multiple prior therapies. Lantern's Radr platform identified PTGR1 as a key predictive biomarker; greater than 87% of Phase 1a patients exceeded the bioactivation threshold, with a diagnostic-ready molecular assay enabling patient selection and/or stratification. The Phase 1a study enrolled 63 patients with advanced solid tumors who had received a median of three prior lines of therapy. A 62-year-old male patient with stage 4 squamous NSCLC harboring a BRCA1 alteration, who had failed radiation and durvalumab, began LP-184 treatment in December 2023 and continues on therapy with more than 23 months of clinical benefit and 22% target lesion reduction. A 50-year-old male patient with stage 4 thymic carcinoma with a CHEK2 alteration, who had progressed through four prior lines including pembrolizumab, started LP-184 in November 2023 and remains on treatment with more than 12 months of benefit and 26% target lesion reduction. A 62-year-old female patient with stage 4 gastrointestinal stromal tumor harboring an ATM alteration, who had failed four prior therapies including sunitinib, initiated LP-184 in November 2023 and continues treatment with more than 12 months of benefit and 9% tumor reduction. The trial met all primary endpoints for safety and tolerability and established a clear Recommended Phase 2 Dose with a wide therapeutic window.
